

PROGEN CORPORATE FACTSHEET

Corporate Factsheet
 About Progen
 Board & Management Team
 Corporate Overview
 Financial Overview

ABOUT PROGEN

Progen is a globally focused biotechnology company headquartered in Brisbane with offices in San Francisco and North Carolina, USA.

The company draws on considerable expertise and intellectual property across three biological platforms, angiogenesis, epigenetics and cell proliferation.

BOARD & MANAGEMENT

Mal Eutick	Independent Non-Executive Chairman
Patrick Burns	Independent Non-Executive Director
John Zalberg	Independent Non-Executive Director
Stephen Chang	Non-Executive Director
John Lee	Independent Non-Executive Director
Robert Williamson	Independent Non-Executive Director
Justus Homburg	CEO
Linton Burns	COO / Company Secretary
Dr Laurence Marton	Chief Scientific Officer
Sarah Meibusch	VP, Business Development
Dr James Garner	VP, Clinical & Medical

CORPORATE OVERVIEW

Progen Pharmaceuticals Limited (the Company) is a dual listed Australian company. Our primary listing is on the Australian Securities Exchange (ASX) and our secondary listing is on the US NASDAQ Global Market (NASDAQ).

CORPORATE GOVERNANCE

The Board has the ultimate responsibility for the strategy and performance of the Company on behalf of the shareholders to whom they are accountable. The Board are committed to achieving and demonstrating the highest standard of corporate governance through setting values and policies which underlie business activities ensuring transparency and protecting stakeholder's interests.

OUR VISION

Progen's vision is two-fold: to improve cancer patients' lives by providing them with improved oncology solutions; and, to create long-term shareholder value through the discovery and development of novel cancer therapeutics.

OUR MISSION

- Maintain and develop our world-class leadership position in the design and development of therapeutics that disrupt the

protein-carbohydrate interactions involved in cancer;

- Effectively and aggressively pursue the clinical and commercial development of therapeutics based on our proprietary chemistry;
- Create an extended portfolio of oncology solutions that can be brought through clinical development for commercialisation;
- Maintain and develop the trust of employees, customers and shareholders by communicating consistently and delivering on our commitments; and
- Foster and encourage a corporate culture of innovation, creativity, confidence, commitment, and teamwork.

FINANCIAL OVERVIEW

- ASX (PGL) and NASDAQ (PGLA)
- Total number of fully paid ordinary shares on issue: 60.3M
- Total listed options outstanding: 2.97M
- Market capitalisation 30 June 2008: ~AU\$ 83 million (~US\$ 74 million)
- Cash position as at 30 June 2008: ~AU\$ 76.7 million, excluding creditors and accruals of \$6.2 million (unaudited).